The acquisition expands Medtronic’s portfolio of advanced cardiac ablation products, according to a Jan. 10 news release. Affera’s technologies include the Affera Prism-1 cardiac mapping and navigation platform and the Sphere-9 cardiac ablation catheter.
Terms of the acquisition were not disclosed. The deal is expected to close in the first half of Medtronic’s fiscal year 2023.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.